|
|
||||||||
The Journal of Immunology, Vol 143, Issue 4 1198-1205, Copyright © 1989 by American Association of Immunologists
ARTICLES |
S Heidenreich, JH Gong, A Schmidt, M Nain and D Gemsa
Institute of Immunology, University of Marburg, West Germany.
The macrophage-activating properties of murine recombinant granulocyte- macrophage (GM)-CSF were studied in murine peritoneal macrophages with respect to metabolism, endocytosis, PGE2 and TNF-alpha release, and tumor cytotoxicity. GM-CSF was found to be a potent stimulus for RNA and protein synthesis, glucose consumption, pinocytosis, and FcR- independent phagocytosis. Macrophages were activated by GM-CSF to kill TNF-alpha-insensitive Eb lymphoma cells but failed to generate cytotoxicity against TNF-alpha-sensitive L929 cells. Although GM-CSF alone was incapable of stimulating TNF-alpha release, it primed macrophages for elevated TNF-alpha production in response to IFN-gamma plus LPS. The priming effect of GM-CSF disappeared upon longer incubation (greater than 12 h) and was followed by a strongly reduced responsiveness to stimuli that release TNF-alpha. Late-stage suppression could be reverted by treatment with the cyclooxygenase blocker indomethacin, and GM-CSF-induced priming for enhanced TNF-alpha release was entirely restored. The responsible arachidonic acid product mediating suppression was found to be PGE2, because 1) GM-CSF-primed macrophages released enhanced amounts of PGE2 and 2) indomethacin- restored macrophages were again suppressed when exogenous PGE2 was added back in amounts produced by GM-CSF-primed macrophages. Although GM-CSF potently induced TNF-alpha gene transcription by 20 h of treatment, PGE2 interfered with translation into the secreted TNF-alpha protein. These data show that GM-CSF is capable of priming for the enhanced release of two factors, initially for TNF-alpha and subsequently for PGE2. The temporally delayed generation of these two mediators suggests an autoregulatory circuit in which the later produced PGE2 limits GM-CSF-induced macrophage activation.
This article has been cited by other articles:
![]() |
A. J. Rosenbloom, P. K. Linden, A. Dorrance, N. Penkosky, M. H. Cohen-Melamed, and M. R. Pinsky Effect of Granulocyte-Monocyte Colony-Stimulating Factor Therapy on Leukocyte Function and Clearance of Serious Infection in Nonneutropenic Patients Chest, June 1, 2005; 127(6): 2139 - 2150. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Flohe, J. Bruggemann, C. Herder, C. Goebel, and H. Kolb Enhanced proinflammatory response to endotoxin after priming of macrophages with lead ions J. Leukoc. Biol., March 1, 2002; 71(3): 417 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Riopel, M. Tam, K. Mohan, M. W. Marino, and M. M. Stevenson Granulocyte-Macrophage Colony-Stimulating Factor-Deficient Mice Have Impaired Resistance to Blood-Stage Malaria Infect. Immun., January 1, 2001; 69(1): 129 - 136. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |